Recall Alerts – Page 2 – Drug Regulatory Authority of Pakistan

Recall Alert: Substandard Products Declared By Provincial Drug Testing Laboratories.

Muhammad Ayub Naveed Recall Alerts February 7, 2025February 7, 2025

Recall Alert

DRAP Alert No	N^oI/S/01-25-16
Action Date	7^th January 2025.
Target Audience	– National Regulatory Field Force. – Pharmacists and Chemists in Distribution, Pharmacies and Medical Stores – Healthcare Professionals – Physicians, Pharmacists, and Nurses at hospitals and clinics – General Public
Problem / Issue	Directorate of Drug Control (DDC) Punjab has informed DRAP that samples of below product have been reported as substandard due to the presence of impurities by the Drug Testing Laboratory (DTL) Lahore.

Therapeutic Goods (s) Affected: –

Product Names	Composition	Batch Details	Manufactured by
AMLOShine 10mg	(Amlodipine 10mg)	Batch No. 7180	Sunshine Pharmaceuticals, Khan Payara, Near Saim Nala, Eimanabad road, Gujranwala
Bytec tablet	(Cetrizine 2HCl 10mg)	Batch No. E088	Batala Pharmaceuticals, 23/B Small Industrial Estate #2, Gujranwala

Risk Statement:	Use of substandard products can lead to therapy failure, which can increase chances of complications in susceptible users including immunocompromised patients, pediatric and geriatric populations.
Action Initiated	– The regulatory field force of DRAP and Provincial Drug Control departments has been directed to immediately conduct market surveys for detection and removal of these products from the market. – All pharmacists and chemists working at distributors and pharmacies should immediately check their stocks and stop supplying these products. The remaining stocks should be quarantined, and the information of their supplier should be immediately provided to their area drug inspector to ensure the removal of falsified product. –Distributors and pharmacies are advised to be vigilant and report any suspected batch of the product(s) in the supply chain to the DRAP using the online form, or by Email at gsms@dra.gov.pk. –Regulatory field force of all federating units (DRAP, Provincial Health Departments, and States) has also increased the surveillance in the market to ensure the effective recall of defective product(s).
Advice for Healthcare Professionals	DRAP requests to enhance vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by this defective batch of the product. -Adverse reactions or quality problems experienced with this product may be reported to the National Pharmacovigilance Centre(NPC), DRAP using the Adverse Event Reporting Form or online through this link. -Please click here for further information on problem reporting to DRAP.
Advice for Consumers	-Consumers should stop using these product bearing the affected batch number(s). They shall contact their physician or healthcare provider(s) if they have experienced any problem that may be related to using this product. -All therapeutic products must be obtained from authorized licensed pharmacies /outlets. Their authenticity and condition should be carefully checked. If you have any doubts, please seek advice from your pharmacist.

Rapid Alert: Crackdown Against Falsified Products

Muhammad Ayub Naveed Recall Alerts February 7, 2025February 7, 2025

Download

Rapid Alert

DRAP Alert No	N^oI/S/02-25-15
Action Date	7th January, 2025
Target Audience	1· National Regulatory Field Force of DRAP and Provincial Drug Control Departments 2· Healthcare Professionals (Physicians, Pharmacists & Nurses) 3. General Public
Problem Statement	Provincial Government Analyst, Drug Testing Laboratory Karachi has informed DRAP that samples below product has been identified as spurious (falsified):

The product identification details are as under:

Therapeutic goods affected:

Product	Batch No*	Mfg Date	Exp. Date	Manufacturer Name (as per label)	Remarks
Evosef 250mg capsule (Cephradine 250mg)	HF-001			Purported to be manufactured by East Pharmaceutical 19-Km Sheikhupura road, Lahore	Spurious. Cephradine not identified
Tramaking-225 Mega tablet (Tramadol HCl 225mg)	TRD2002			Name of Manufacturer not mentioned	Spurious

Risk Statement:	Falsified products having no active ingredient or identification of manufacturer pose a great risk to the health of patient and can cause adverse drug reactions or may lead to therapy failure that can result in fatal consequences.
Action Initiated	The Regulatory field force has been directed to conduct surveillance activities throughout the supply chain to confiscate the counterfeit product. All Pharmacists, chemists, and other healthcare professionals working at distributions, pharmacies, healthcare facilities, and other aspects of the supply chain system should immediately check the stock, and information related to the supplier of such product should be provided to the Regulatory field force (DRAP, Provincial Drug Control Departments) to ensure the removal of this product from the circulation.
Advice for Healthcare Professionals	All pharmacists and chemist working at distributions and pharmacies should immediately check their stocks and stop supplying mentioned products. The remaining stocks should be quarantined and returned to the supplier/company. Regulatory field force of all federating units (DRAP and Provincial Health Departments) are advised to increase surveillance in the market to ensure the effective removal of this products. Any adverse events or quality problems experienced with the use of these products should be reported to National or Provincial pharmacovigilance centers using Adverse Event Reporting Form or online through this link. Further information on reporting problems to DRAP is available at this link.
Advice for Consumer	Consumers in possession of mentioned batches should immediately report to Drug Regulatory Authority of Pakistan and contact to their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product and report the same to DRAP through Adverse Event Reporting Form or online through this link.

Rapid Alert: Presence of Counterfeit and Trademark Infringement Case of Laroscorbine Platinum Injection in the Market

Muhammad Ayub Naveed Recall Alerts February 4, 2025February 6, 2025

Download

Rapid Alert

DRAP Alert No	N^oI/S/02-25-14
Action Date	4th February, 2025
Target Audience	1· National Regulatory Field Force of DRAP and Provincial Drug Control Departments 2· Healthcare Professionals (Physicians, Pharmacists & Nurses) 3. General Public
Problem Statement	M/s Roche Pakistan Limited, Karachi, has notified DRAP, regarding the sale of counterfeit ‘Laroscorbine Platinum Injection’ in the market across Pakistan. According to the principal, Roche manufactured and marketed Laroscorbine until 2005. In that year, Roche sold the product and brand to Bayer AG. Therefore, any Laroscorbine offered for sale, and which is labeled with the Roche logo or which claims that it was manufactured or marketed by Roche, is not a genuine Roche product. Further informed that as the product does not belong to Roch portfolio, tracing of the lot is not possible:

The product identification details are as under:

Therapeutic goods affected:

Product	Batch No*	Mfg Date	Exp. Date	Manufacturer Name (as per label)	Remarks
*Laroscorbine Platinum Injection* Reg. No. 0326422				Purported to be manufactured by M/s Roche Pakistan Limited, Karachi.	Spurious

Risk Statement:	The use of Laroscorbine Platinum Injection is believed to brighten the skin and maintain skin elasticity. However, the administration of counterfeit productscould result in treatment failure, worsening of the disease, or life threatening consequences
Action Initiated	The Regulatory field force has been directed to conduct surveillance activities throughout the supply chain to confiscate the counterfeit product. All Pharmacists, chemists, and other healthcare professionals working at distributions, pharmacies, healthcare facilities, and other aspects of the supply chain system should immediately check the stock, and information related to the supplier of such product should be provided to the Regulatory field force (DRAP, Provincial Drug Control Departments) to ensure the removal of this product from the circulation.
Advice for Healthcare Professionals	All pharmacists and chemist working at distributions and pharmacies should immediately check their stocks and stop supplying mentioned products. The remaining stocks should be quarantined and returned to the supplier/company. Regulatory field force of all federating units (DRAP and Provincial Health Departments) are advised to increase surveillance in the market to ensure the effective removal of this products. Any adverse events or quality problems experienced with the use of these products should be reported to National or Provincial pharmacovigilance centers using Adverse Event Reporting Form or online through this link. Further information on reporting problems to DRAP is available at this link.
Advice for Consumer	Consumers in possession of mentioned batches should immediately report to Drug Regulatory Authority of Pakistan and contact to their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product and report the same to DRAP through Adverse Event Reporting Form or online through this link.

Recall Alert: Substandard Flagyl Injection Batch No. Ad482 Manufactured by M/S. Sanofi Aventis Pakistan Limited, Karachi.

Muhammad Ayub Naveed Recall Alerts January 28, 2025January 28, 2025

Recall Alert

Download

DRAP Alert No	N^oI/S/01-25-13
Action Date	28^th January 2025.
Target Audience	– National Regulatory Field Force. – Pharmacists and Chemists in Distribution, Pharmacies and Medical Stores – Healthcare Professionals – Physicians, Pharmacists, and Nurses at hospitals and clinics – General Public
Problem / Issue	Senior Drug Inspector ICT Islamabad has informed DRAP that samples below product has been reported substandard by Drug Testing Laboratory (DTL) Rawalpindi:

Therapeutic Goods (s) Affected: –

Product Names	Composition	Batch Details	Manufactured by
Flagyl Injection 100ml	Metronidazole 500mg	Batch No. AD482	M/s. Sanofi Aventis Pakistan Limited, Plot No. 23, Sector 22, Korangi industrial area, Karachi

Risk Statement:	Endotoxin containing intravenous products can lead to a range of consequences, including fever, chills, shock, organ failure, which can even prove fatal. Even small amounts of endotoxin in an injection can cause significant harm, particularly in vulnerable individuals like immunocompromised patients or those with pre-existing medical conditions.
Action Initiated	– The regulatory field force of DRAP and Provincial Drug Control departments has been directed to immediately conduct market surveys for detection and removal of these products from the market. – All pharmacists and chemists working at distributors and pharmacies should immediately check their stocks and stop supplying these products. The remaining stocks should be quarantined, and the information of their supplier should be immediately provided to their area drug inspector to ensure the removal of falsified product. –Distributors and pharmacies are advised to be vigilant and report any suspected batch of the product(s) in the supply chain to the DRAP using the online form, or by Email at gsms@dra.gov.pk. –Regulatory field force of all federating units (DRAP, Provincial Health Departments, and States) has also increased the surveillance in the market to ensure the effective recall of defective product(s).
Advice for Healthcare Professionals	DRAP requests to enhance vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by this defective batch of the product. -Adverse reactions or quality problems experienced with this product may be reported to the National Pharmacovigilance Centre(NPC), DRAP using the Adverse Event Reporting Form or online through this link. -Please click here for further information on problem reporting to DRAP.
Advice for Consumers	-Consumers should stop using these product bearing the affected batch number(s). They shall contact their physician or healthcare provider(s) if they have experienced any problem that may be related to using this product. -All therapeutic products must be obtained from authorized licensed pharmacies /outlets. Their authenticity and condition should be carefully checked. If you have any doubts, please seek advice from your pharmacist.

Rapid Alert: Presence of Falsified Mirzpan Suspension 100mg/5ml Purportedly Manufactured by M/s. Miraz Pharma, Kasur.

Muhammad Ayub Naveed Recall Alerts January 23, 2025January 27, 2025

Download

Rapid Alert

DRAP Alert No	N^oI/S/01-25-12
Action Date	23rd January, 2025
Target Audience	1· National Regulatory Field Force of DRAP and Provincial Drug Control Departments 2· Healthcare Professionals (Physicians, Pharmacists & Nurses) 3. General Public
Problem Statement	Secretary, PQCB Balochistan, has informed DRAP that sample of following product, manufactured by M/s Miraz Pharma, Kasur, has been declared “*Spurious”, “Unregistered” and “Misbranded” by the Drug Testing Laboratory, Quetta. The sample portion “Suspension Mirzpan*” contains no Active Pharmaceutical Ingredient (Cefixime), bears a fake registration number in seven digits, and exhibit a pH value of 6.51, which is outside the USP specified range of 2.5 – 4.5. Additionally, the outer packaging contains multiple spelling errors, as well as ambiguous and misleading information. The details of sample are as under::

The product identification details are as under:

Therapeutic goods affected:

Product	Batch No*	Mfg Date	Exp. Date	Manufacturer Name (as per label)	Remarks
Mirzpan Suspension 100mg / 5ml Reg. No. 0326422	007	11-2023	11-2025	Purported to be manufactured by M/s Miraz Pharma, Plot No. 23, Qasoor Industries, Kasur.	Spurious

Risk Statement:	The presence of falsified cefixime suspension poses significant risks to patient health, including potential therapeutic failure, inadequate treatment of bacterial infections, and the development of antibiotic resistance.
Action Initiated	The field force under administrative control of DRAP and Provincial Drug Control departments have been directed to immediately conduct market surveys for detection of presence and removal of mentioned batches from the market.
Advice for Healthcare Professionals	All pharmacists and chemist working at distributions and pharmacies should immediately check their stocks and stop supplying mentioned products. The remaining stocks should be quarantined and returned to the supplier/company. Regulatory field force of all federating units (DRAP and Provincial Health Departments) are advised to increase surveillance in the market to ensure the effective removal of this products. Any adverse events or quality problems experienced with the use of these products should be reported to National or Provincial pharmacovigilance centers using Adverse Event Reporting Form or online through this link. Further information on reporting problems to DRAP is available at this link.
Advice for Consumer	Consumers in possession of mentioned batches should immediately report to Drug Regulatory Authority of Pakistan and contact to their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product and report the same to DRAP through Adverse Event Reporting Form or online through this link.

Recall Alert: Recall of Adulterated Safemed Infusion Batch No. SJU-0824 Manufactured by M/s Ahad International Pharmaceuticals Ltd, Dera Ismail Khan

Muhammad Ayub Naveed Recall Alerts January 17, 2025January 17, 2025

Recall Alert

Download

DRAP Alert No	N^oI/S/01-25-11
Action Date	16^th January 2025.
Target Audience	– National Regulatory Field Force. – Pharmacists and Chemists in Distribution, Pharmacies and Medical Stores – Healthcare Professionals – Physicians, Pharmacists, and Nurses at hospitals and clinics – General Public
Problem / Issue	The Senior Drug Inspector, District Health Office, Quetta collected the samples of Infusion Safemed and sent them for test and analysis. The Provincial Drug Testing Laboratory, Quetta, has declared the following batch of Infusion Safemed, manufactured by M/s. Ahad International Pharmaceuticals Ltd., Sheikhupura, as Adulterated. The injection was found to contain foreign matter, which is visible to the naked eye:

Therapeutic Goods (s) Affected: –

Product Names	Composition	Batch Details	Manufactured by
Safemed 500mg Infusion Reg. No. 045824	Metronidazole	Batch No. SJU-0824	M/s. Ahad International Pharmaceuticals Ltd. 13-Km, Gomal University, Multan Road Dera Ismail Khan

Risk Statement:	An injectable product that contains foreign matter is considered adulterated and may compromise the standard quality of the drug, as it may not be sterile. Sterility is a fundamental quality attribute for all injectable drugs. The presence of adulterated material can lead to serious adverse reactions in patients, including, but not limited to, the following: (i) Anaphylactic shock, which can be fatal. (ii) Skin rashes, itching, and difficulty in breathing. (iii) Suboptimal or no therapeutic effect for the intended medical treatment.
Action Initiated	– The regulatory field force of DRAP and Provincial Drug Control departments has been directed to immediately conduct market surveys for detection and removal of these products from the market. – All pharmacists and chemists working at distributors and pharmacies should immediately check their stocks and stop supplying these products. The remaining stocks should be quarantined, and the information of their supplier should be immediately provided to their area drug inspector to ensure the removal of falsified product. –Distributors and pharmacies are advised to be vigilant and report any suspected batch of the product(s) in the supply chain to the DRAP using the online form, or by Email at gsms@dra.gov.pk. –Regulatory field force of all federating units (DRAP, Provincial Health Departments, and States) has also increased the surveillance in the market to ensure the effective recall of defective product(s).
Advice for Healthcare Professionals	DRAP requests to enhance vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by this defective batch of the product. -Adverse reactions or quality problems experienced with this product may be reported to the National Pharmacovigilance Centre(NPC), DRAP using the Adverse Event Reporting Form or online through this link. -Please click here for further information on problem reporting to DRAP.
Advice for Consumers	-Consumers should stop using these product bearing the affected batch number(s). They shall contact their physician or healthcare provider(s) if they have experienced any problem that may be related to using this product. -All therapeutic products must be obtained from authorized licensed pharmacies /outlets. Their authenticity and condition should be carefully checked. If you have any doubts, please seek advice from your pharmacist.

Recall Alert: Substandard Product “Incip Infusion 100ml” Batch No. Cpv-147 Mfg. By Inventor Pharma (Pvt.) Ltd., Karachi.

Muhammad Ayub Naveed Recall Alerts January 16, 2025January 16, 2025

Recall Alert

Download

DRAP Alert No	N^oI/S/01-25-10
Action Date	16^th January 2025.
Target Audience	– National Regulatory Field Force. – Pharmacists and Chemists at Distribution, Pharmacies and Medical Stores – Healthcare Professionals- Physicians, Pharmacists, and Nurses at hospital and clinics – General Public
Problem / Issue	Directorate of Drugs Control (DDC) Punjab has informed DRAP that samples below product has been reported substandard by Drug Testing Laboratory (DTL) Lahore:

Therapeutic Good(s) Affected: –

Product Names	Composition	Batch Details	Manufactured by
Incip Infusion 100ml	Ciprofloxacin (as lactate) 200mg	Batch No. CPV-147	Inventor Pharma (Pvt.) Ltd., Plot No. K/196, S.I.T.E. (SHW) PH-II, Karachi.

Risk Statement:	The use of substandard injection may pose serious health risks to patients, including reduced efficacy or lack of therapeutic effect and increased risk of adverse drug reactions such as allergic reactions, anaphylaxis, and hypersensitivity reactions.
Action Initiated	-The regulatory field force of DRAP and Provincial Drug Control departments has been directed to immediately conduct market surveys for detection and removal of these products from the market. All pharmacists and chemists working at distributors and pharmacies should immediately check their stocks and stop supplying these products. The remaining stocks should be quarantined, and the information of their supplier should be immediately provided to their area drug inspector to ensure the removal of falsified product. –Distributors and pharmacies are advised to be vigilant and report any suspected batch of the product(s) in the supply chain to the DRAP using the online form, or by Email at gsms@dra.gov.pk. –Regulatory field force of all federating units (DRAP, Provincial Health Departments, and States) has also increased the surveillance in the market to ensure the effective recall of defective product(s).
Advice for Healthcare Professionals	DRAP requests to enhance vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by this defective batch of the product. -Adverse reactions or quality problems experienced with this product may be reported to the National Pharmacovigilance Centre(NPC), DRAP using the Adverse Event Reporting Form or online through this link. -Please click here for further information on problem reporting to DRAP.
Advice for Consumers	-Consumers should stop using these product bearing the affected batch number(s). They shall contact their physician or healthcare provider(s) if they have experienced any problem that may be related to using this product. -All therapeutic products must be obtained from authorized licensed pharmacies /outlets. Their authenticity and condition should be carefully checked. If you have any doubts, please seek advice from your pharmacist.

Rapid Alert: Crackdown Against Falsified Products

Muhammad Ayub Naveed Recall Alerts January 16, 2025January 16, 2025

Download

Rapid Alert

DRAP Alert No	N^oI/S/01-25-09
Action Date	16th January, 2025
Target Audience	1· National Regulatory Field Force of DRAP and Provincial Drug Control Departments 2· Healthcare Professionals (Physicians, Pharmacists & Nurses) 3. General Public
Problem Statement	Directorate of Drugs Control (DDC) Punjab has informed DRAP that samples below product has been identified as spurious (falsified):

The product identification details are as under:

Therapeutic goods affected:

Product	Batch No*	Mfg Date	Exp. Date	Manufacturer Name (as per label)	Remarks
Duphaston tablet (Dydrogesterone 10mg)	233493	–	–	Purported to be manufactured by Highnoon Laboratories Ltd., Lahore	Spurious
Depasrone tablet (Dydrogesterone 10mg)	0363			Purported to be manufactured by Alpine Laboratories, Karachi (Fictitious firm)	Spurious

Risk Statement:	The impact of the use of falsified products may lead to sub-optimal therapeutic effects whereas the use of a spurious product will lead to therapy failure or other associated problems.
Action Initiated	The field force under administrative control of DRAP and Provincial Drug Control departments have been directed to immediately conduct market surveys for detection of presence and removal of mentioned batches from the market.
Advice for Healthcare Professionals	All pharmacists and chemist working at distributions and pharmacies should immediately check their stocks and stop supplying mentioned products. The remaining stocks should be quarantined and returned to the supplier/company. Regulatory field force of all federating units (DRAP and Provincial Health Departments) are advised to increase surveillance in the market to ensure the effective removal of this products. Any adverse events or quality problems experienced with the use of these products should be reported to National or Provincial pharmacovigilance centers using Adverse Event Reporting Form or online through this link. Further information on reporting problems to DRAP is available at this link.
Advice for Consumer	Consumers in possession of mentioned batches should immediately report to Drug Regulatory Authority of Pakistan and contact to their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product and report the same to DRAP through Adverse Event Reporting Form or online through this link.

Rapid Alert: CRACKDOWN AGAINST FALSIFIED PRODUCT

Muhammad Ayub Naveed Recall Alerts January 16, 2025January 16, 2025

Download

Rapid Alert

DRAP Alert No	N^oI/S/01-25-08
Action Date	16th January, 2025
Target Audience	1· National Regulatory Field Force of DRAP and Provincial Drug Control Departments 2· Healthcare Professionals (Physicians, Pharmacists & Nurses) 3. General Public
Problem Statement	Directorate of Drugs Control (DDC) Punjab has informed DRAP that samples below product has been identified as spurious (falsified):

The product identification details are as under:

Therapeutic goods affected:

Product	Batch No*	Mfg Date	Exp. Date	Manufacturer Name (as per label)	Remarks
D-Gest tablet (Dydrogesterone 10mg)	DGH003	–	–	Purported to be manufactured by Mass Pharma (Pvt.) Ltd., Lahore	Spurious

Risk Statement:	The impact of the use of falsified products may lead to sub-optimal therapeutic effects whereas the use of a spurious product will lead to therapy failure or other associated problems.
Action Initiated	The field force under administrative control of DRAP and Provincial Drug Control departments have been directed to immediately conduct market surveys for detection of presence and removal of mentioned batches from the market.
Advice for Healthcare Professionals	All pharmacists and chemist working at distributions and pharmacies should immediately check their stocks and stop supplying mentioned products. The remaining stocks should be quarantined and returned to the supplier/company. Regulatory field force of all federating units (DRAP and Provincial Health Departments) are advised to increase surveillance in the market to ensure the effective removal of this products. Any adverse events or quality problems experienced with the use of these products should be reported to National or Provincial pharmacovigilance centers using Adverse Event Reporting Form or online through this link. Further information on reporting problems to DRAP is available at this link.
Advice for Consumer	Consumers in possession of mentioned batches should immediately report to Drug Regulatory Authority of Pakistan and contact to their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product and report the same to DRAP through Adverse Event Reporting Form or online through this link.

Rapid Alert: Presence of Counterfeit Ocrevus 300mg/10ml Solution for Injection Manufactured by Ms Roche Diagnostics GmbH, Mannheim, Almanya

Muhammad Ayub Naveed Recall Alerts January 14, 2025January 15, 2025

Download

Rapid Alert

DRAP Alert No	N^oI/S/01-25-08
Action Date	14th January, 2025
Target Audience	· National Regulatory Field Force of DRAP and Provincial Drug Control Departments · Healthcare Professionals (Physicians, Pharmacists & Nurses) · General Public
Problem Statement	TM/s Roche Pakistan Limited, Karachi, has notified DRAP, regarding the circulation of counterfeit Ocrevus 300mg/10ml Solution for Injection in the market across Pakistan. Investigation carried out by Roche Global revealed that the genuine product, batch H0041B27, was originally distributed to Turkey in August 2020 and expired on 07-02-2022, while the counterfeit sample displayed expiry date of 05-09-2025. These discrepancies confirmed the product as counterfeit. Details of counterfeit product are as follows:

S#	Product Name	Composition	Batch No.	Manufactured by (as per label claim)	Lab Test Results
1	Ocrevus Solution for Injection, 300mg/10ml	(Ocrelizumab)	H0041B27	M/s Roche Diagnostics GmbH, Mannheim, Almanya.	Counterfeit

Risk Statement:	Ocrelizumab is a humanized monoclonal antibody used in the treatment of multiple sclerosis. The use of counterfeit productcould result in treatment failure, worsening of the disease, or life threatening consequences.
Action Initiated	The Regulatory Field Force has been directed to increase surveillance throughout the supply chain to confiscate the mentioned product. All Pharmacists, chemists, and other healthcare professionals working at distributions, pharmacies, healthcare facilities, and other aspects of the supply chain system should immediately check the stock, and information related to the supplier of such product should be provided to the Regulatory field force (DRAP, Provincial Health Departments and States) to ensure the removal of this product from the circulation.
Advice for Healthcare Professionals	DRAP requests increased vigilance within the supply chains of institutions/pharmacies/healthcare facilities likely to be affected by this product. Further information on reporting problems to DRAP is available at this link. Any adverse events or quality problems experienced with the use of these products should be reported to the National or Provincial pharmacovigilance centers using Adverse Event Reporting Form or online through this link. Further information on reporting problems to DRAP is available on this link.
Advice for Consumer	Consumers should not use these products and should contact their physician or healthcare provider(s) if they have experienced any problem related to taking or using these products and should report the incident to the Drug Regulatory Authority of Pakistan / National Pharmacovigilance Centre.

All therapeutic goods must be obtained from licensed pharmacies and other authorized/licensed retail outlets. The authenticity and condition of products should be carefully checked. Seek advice from your pharmacists or other healthcare professionals in case of any doubt.